AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
James Rock email@example.com
AriBio USA Branch
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTIMindtree and SNP Partner To Launch “Fast Forward” For BLUEFIELD™ Implementation8.6.2023 11:45:00 CEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, in collaboration with SNP Schneider-Neureither & Partner SE (ISIN: DE0007203705), a world-leading provider of software solutions for digital transformation processes, automated data migrations and data management in the SAP environment, today announced the launch of “Fast Forward” for BLUEFIELD™ implementation, powered by SNP’s proprietary approach. The joint offering – “Fast Forward” – is a full lifecycle solution built to accelerate an enterprise’s migration to the SAP S/4HANA platform with minimal risk, while retaining the golden nugget of existing ERP. It combines LTIMindtree’s global S/4HANA capability and industry knowledge with SNP’s CrystalBridge® platform and Rapid Empty Shell Creation technology to transform existing SAP investments without having to fully redesign their legacy systems. As part of the partnership, LTIMindtree and SNP will also set up a joint innovation center t
SAP S/4HANA is Driving Nordics in a Digital Direction8.6.2023 10:00:00 CEST | Press release
Enterprise demand for SAP transformation services in the Nordics has grown exponentially over the past 12 months, as companies seek industry-specific solutions and accelerate their cloud transformations,according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2023 ISG Provider Lens™ SAP Ecosystem report for the Nordics finds the planned phase-out of support for SAP’s ERP Central Component (ECC) in 2027 has led to increased adoption of SAP S/4HANA. In the Nordic region, RISE with SAP, a unified ERP-as-a-service offering, has played a major role in enterprises embracing SAP in the cloud. “There is a rising call in the Nordics for increased SAP cloud services,” said Anthony Drake, ISG director, North Europe. “Providers have responded by extending their partnerships both with SAP and with hyperscalers.” Expansion of the SAP market has led to a growing focus on certification and training
Stallergenes Greer Foundation Science Awards for Allergy 2023: Call for Applications8.6.2023 10:00:00 CEST | Press release
The Stallergenes Greer Foundation aims to create healthier futures for all. The Foundation, under the aegis of the Fondation de France, is philanthropically dedicated to three focus areas: Advancing scientific research to bolster innovation and precision medicine. Supporting academic initiatives to further develop future generations of allergy healthcare professionals. Engaging in climate action and environmental protection to progress the prevention and treatment of allergies. Submissions are open for the Stallergenes Greer Foundation Science Awards for Allergy 2023. A total of €150,000 will be awarded for outstanding work led either by a young scientist or a mid-career scientist to advance precision medicine in the field of allergy, or outstanding work in the environmental field to advance the prevention and treatment of allergies. The Stallergenes Greer Foundation Science Awards for Allergy are presented in two areas: - Innovation Awards: two awards will be presented either to encou
Europcar Selects BringOz to Digitize and Streamline Vehicle Movements In Switzerland8.6.2023 09:00:00 CEST | Press release
As the largest vehicle rental company in Switzerland, Europcar’s fleet encompasses 5,500 vehicles including small cars, family vans, luxury sedans, commercial vehicles, convertibles and more. With over 90 locations, Europcar provides convenient pick-up and drop-off stations throughout Switzerland. Europcar Switzerland has chosen to work with BringOz’ logistics platform as part of its overall efforts to digitize internal processes and achieve the following goals: Automate and Optimize Vehicle Movements: BringOz digitizes vehicle movements and matches vehicle supply with consistently changing demand. The Europcar team will plan, execute and monitor vehicle transfer across all locations. Streamline Processes and Maximize Resources: The Europcar team will streamline processes, save time and reduce costs by increasing the efficiency of vehicle transfers with consolidation and better use of resources. Improve Team Productivity and Drive Revenue Growth: The Europcar team will focus more time
SES Space & Defense Delivers Satellite Connectivity to AWS Modular Data Center for the U.S. Department of Defense8.6.2023 08:50:00 CEST | Press release
SES Space & Defense, a wholly-owned subsidiary of SES, today announced the availability of flexible, secure, and reliable satellite-powered network connectivity for AWS Modular Data Center. AWS Modular Data Center makes it easy for the U.S. Department of Defense (DoD) to deploy modular data centers managed by Amazon Web Services (AWS) in infrastructure-limited locations. In February 2023, AWS announced the availability of AWS Modular Data Center to the DoD under the Joint Warfighting Cloud Capability (JWCC) contract. Leveraging SES’s multi-orbit, multi-band global fleet of satellites with AWS Modular Data Center, defense customers can access low-latency, cloud-based applications and services securely in Denied, Disrupted, Intermittent, and Limited (DDIL) environments through a dedicated network connection to AWS Regions. The U.S. DoD customers will also be able to leverage SES’s second-generation medium earth orbit (MEO) constellation, O3b mPOWER, designed with an open architecture app
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom